Alcohol Use Disorder Pipeline Set for Transformational Progress by 2026 with 25+ Therapies and Robust Clinical Momentum from Adial Pharmaceuticals, Imbrium Therapeutics, and BioCorRx | DelveInsight

Alcohol Use Disorder (AUD) companies such as Adial Pharmaceuticals, Imbrium Therapeutics, BioCorRx Pharmaceuticals, Beckley Psytech, Cybin, BioXcel Therapeutics, MediciNova, and others are actively redefining the future of addiction therapeutics through innovative drug development strategies, precision medicine approaches, and expanding clinical pipelines.

DelveInsight's, "Alcohol Use Disorder Pipeline Insight, 2026" report provides comprehensive insights into 25+ companies and 25+ pipeline drugs within the Alcohol Use Disorder pipeline landscape. The report delivers an in-depth evaluation of pipeline drug profiles, including both clinical and nonclinical stage candidates. It further offers a detailed therapeutic assessment based on product type, stage of development, route of administration, and molecule type, while also highlighting inactive pipeline products and discontinued programs.

Discover how next-generation therapies are transforming Alcohol Use Disorder treatment and reshaping long-term recovery outcomes: https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Alcohol Use Disorder Pipeline Report
• The AUD pipeline demonstrates strong growth with 25+ active therapeutic candidates across multiple stages of development.
• Increasing emphasis on precision medicine and genetically targeted therapies is enhancing treatment personalization.
• Novel mechanisms such as nociceptin receptor agonism, serotonergic modulation, and psychedelic-assisted therapy are gaining traction.
• Long-acting formulations and implantable drug delivery systems are being developed to improve patient adherence.
• Strategic collaborations and licensing agreements are accelerating innovation and clinical progress.
• Integration of biomarkers and companion diagnostics is expected to improve patient selection and treatment outcomes.
• The pipeline includes a diverse array of molecule types, including small molecules, biologics, peptides, and novel delivery platforms.
• In April 2026, DemeRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for DMX-1001 (oral noribogaine), a novel neuroplastogen therapeutic for the treatment of alcohol use disorder (AUD).
• In April 2026, Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, announced that CMND-100, the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD) has met the primary endpoint in its FDA-approved Phase I/IIa clinical trial.
• In March 2026, Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, announced the successful completion of treatment and follow-up of 18 participants in its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).
• In a presentation delivered in June 2025, Imbrium Therapeutics indicated that results from the Phase II trial of sunobinop for treating moderate-to-severe AUD are expected in 2026. The company also projected a potential US launch of Sunobinop in 2030.
• According to a news release in June 2025, a University of California, Los Angeles (UCLA) clinical trial found that ibudilast did not significantly reduce alcohol consumption compared to a placebo; however, the drug demonstrated a positive effect among female participants.
• In June 2025, Imbrium Therapeutics presented updates on its pipeline developments at the BIO International Convention held on Wednesday, June 18. The company is actively seeking strategic partnerships to advance the development of its investigational therapeutics targeting multiple indications across diverse disease areas, including genitourinary disorders, substance use disorders, and oncology.
• In May 2025, Altimmune enrolled the first subject in the RECLAIM Phase II trial evaluating the efficacy and safety of pemvidutide in subjects with AUD.
• In March 2025, Tempero Bio announced the closing of a USD 70 million Series B financing. The financing was led by 8VC with participation from Aditum Bio, Khosla Ventures, and other investors. The proceeds will be used to advance TMP-301 through two Phase II clinical trials for AUD and CUD, as well as Phase III-enabling activities and preclinical studies for additional indications and formulations.

Stay informed with comprehensive pipeline analytics and competitive intelligence insights: https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr

Understanding Alcohol Use Disorder: A Complex Neurobiological and Behavioral Condition
Alcohol Use Disorder (AUD), commonly referred to as alcoholism, represents the most severe form of alcohol misuse and is characterized by an inability to control or stop alcohol consumption despite adverse social, occupational, and health consequences. AUD is a chronic relapsing brain disorder with a multifactorial etiology that includes genetic predisposition, environmental influences, neurobiological alterations, and psychological factors.

The condition remains highly prevalent globally, with significant disease burden observed in major healthcare markets such as the United States and Europe. Studies suggest that nearly 50% of the risk for developing AUD is heritable, while the remaining risk is attributed to environmental exposures, including early-life experiences, peer influence, stress, and socioeconomic conditions.

From a pharmacological standpoint, alcohol is classified as a sedative-hypnotic agent that exerts dose-dependent effects on the central nervous system. At lower doses, it may produce stimulant-like effects such as euphoria and increased sociability, whereas higher doses can result in sedation, respiratory depression, coma, and even death. Chronic alcohol consumption impacts virtually every organ system, contributing to liver disease, cardiovascular complications, neurological impairment, and increased cancer risk.

At the neurobiological level, alcohol stimulates the release of dopamine from neurons originating in the ventral tegmental area (VTA), activating the mesolimbic reward pathway. This leads to dopamine release in the nucleus accumbens and prefrontal cortex, reinforcing alcohol-seeking behavior and contributing to addiction. Additionally, alcohol interacts with multiple neurotransmitter systems, including gamma-aminobutyric acid (GABA), glutamate, serotonin (5-HT), corticotropin-releasing factor, and endogenous opioid peptides, creating a complex neurochemical environment that sustains dependence.

Diagnostic approaches for AUD remain largely clinical, supported by standardized criteria and laboratory assessments such as carbohydrate-deficient transferrin (CDT), which serves as a biomarker for chronic heavy alcohol use. However, variability in sensitivity and specificity, along with patient heterogeneity, continues to present diagnostic challenges.

Current treatment strategies include behavioral therapies, counseling, and pharmacological interventions such as naltrexone, acamprosate, and disulfiram. Despite these options, treatment outcomes remain suboptimal due to issues related to patient adherence, relapse rates, and variability in therapeutic response, highlighting the urgent need for innovative and targeted treatment solutions.

Gain deeper insights into evolving treatment paradigms and future therapeutic opportunities in Alcohol Use Disorder: https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr

Evolving Alcohol Use Disorder Pipeline Landscape: Innovation at the Forefront
The Alcohol Use Disorder therapeutic landscape is undergoing a significant transformation, driven by advances in neuroscience, genomics, and precision medicine. The pipeline is increasingly focused on addressing the underlying neurobiological mechanisms of addiction rather than solely managing symptoms.

Emerging therapies are targeting key pathways involved in reward processing, stress response, and impulse control. These include modulation of opioid receptors, glutamatergic signaling, serotonergic systems, and novel targets such as nociceptin receptors and psychedelic-assisted therapies.

DelveInsight's report highlights that approximately 25+ companies are actively engaged in developing therapies for AUD, with over 25 pipeline candidates spanning discovery, preclinical, and clinical stages. The diversification of therapeutic approaches reflects the growing recognition of AUD as a heterogeneous disorder requiring personalized treatment strategies.

Alcohol Use Disorder Emerging Drugs Profile
AD04: Adial Pharmaceuticals
AD04 is a genetically targeted investigational therapy designed to treat AUD by modulating neurotransmitter pathways associated with reward and reinforcement. The drug leverages a proprietary genetic diagnostic test to identify patients who are most likely to benefit from treatment. By balancing serotonergic and dopaminergic activity, AD04 aims to reduce alcohol cravings and heavy drinking behavior. Clinical studies have demonstrated promising results in genetically defined patient subgroups, and the therapy is currently advancing through Phase III clinical trials.

Sunobinop: Imbrium Therapeutics
Sunobinop is a novel, first-in-class oral nociceptin receptor (NOP) agonist that targets neural circuits involved in addiction and stress regulation. The drug is designed to reduce alcohol consumption and prevent relapse by modulating reward and emotional processing pathways. Currently in Phase II clinical development, Sunobinop represents a promising approach to addressing both the physiological and psychological components of AUD.

BICX104: BioCorRx Pharmaceuticals
BICX104 is a long-acting, biodegradable subcutaneous implant delivering naltrexone for extended durations. This innovative formulation is designed to improve treatment adherence by eliminating the need for daily or monthly dosing. Clinical studies have demonstrated sustained therapeutic drug levels for up to 84 days with a favorable safety profile. The drug is currently in Phase I clinical trials and holds significant potential for enhancing long-term treatment outcomes in AUD patients.

Further detailed drug profiles, clinical updates, and competitive benchmarking are included in the full report: https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr

Alcohol Use Disorder Pipeline Segmentation and Therapeutic Assessment
The report provides a comprehensive segmentation of AUD pipeline drugs based on development stage, route of administration, and molecule type.

Alcohol Use Disorder Clinical Trial Phases
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I)
• Preclinical and discovery-stage candidates
• Inactive and discontinued programs

Alcohol Use Disorder Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Alcohol Use Disorder Molecule Types
• Small molecules
• Monoclonal antibodies
• Peptides
• Polymer-based therapies
• Gene therapies
• Recombinant fusion proteins

Alcohol Use Disorder Product Types
• Mono therapies
• Combination therapies
• Mono/Combination approaches

These diverse therapeutic classifications reflect the increasing complexity of drug development in AUD and the need for multifaceted treatment approaches that address both biological and behavioral dimensions of addiction.

Alcohol Use Disorder Clinical Trial and Development Activities
The AUD pipeline is characterized by a surge in clinical trial activity across global markets. Pharmaceutical and biotechnology companies are actively investing in research and development to address unmet medical needs and improve patient outcomes.

Collaborations between industry players and academic institutions are playing a crucial role in advancing scientific understanding and accelerating drug development. Strategic partnerships, licensing agreements, and mergers and acquisitions are further strengthening the competitive landscape.

Key players such as Adial Pharmaceuticals, Imbrium Therapeutics, and BioCorRx Pharmaceuticals are leading innovation with differentiated therapeutic approaches. Meanwhile, emerging companies are exploring cutting-edge modalities such as psychedelic compounds, digital therapeutics, and neuroimmune modulation.

Alcohol Use Disorder Market Drivers, Challenges, and Future Outlook
The growth of the Alcohol Use Disorder pipeline is driven by several key factors, including rising global prevalence, increasing awareness of addiction as a medical condition, and advancements in neuroscience and pharmacology. The growing demand for personalized medicine and improved treatment outcomes is further fueling innovation in this space.
However, the AUD landscape also faces significant challenges. These include high relapse rates, patient heterogeneity, limited availability of predictive biomarkers, and stigma associated with addiction, which can hinder diagnosis and treatment adherence.
Despite these challenges, the future outlook for the AUD pipeline remains highly promising. The integration of artificial intelligence, biomarker discovery, and precision medicine is expected to revolutionize treatment paradigms. Emerging therapies targeting novel pathways and incorporating innovative delivery systems are likely to improve efficacy, safety, and patient compliance.
As more therapies progress through clinical development and approach commercialization, the AUD market is poised for substantial growth, offering new hope for patients and healthcare providers worldwide.

Access detailed insights into clinical trials, partnerships, and innovation strategies shaping the AUD pipeline: https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr

Scope of the Alcohol Use Disorder Pipeline Report
• Coverage: Global
• Key Companies: Cybin, Indivio, BioXcel Therapeutics, BioCorRx Pharmaceuticals, Beckley Psytech, MediciNova, Adial Pharmaceuticals, Imbrium Therapeutics, and others
• Key Therapies: CYB003, INDV1000, BXCL501, BICX104, BPL-003, MN-166, AD04, Sunobinop
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stage: Discovery, Preclinical, Phase I, Phase II, Phase III

Table of Contents
1. Introduction
2. Executive Summary
3. Alcohol Use Disorder Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Analytical Perspective
7. Late-Stage Products
8. Mid-Stage Products
9. Early-Stage Products
10. Inactive Products
11. Key Companies
12. Key Products
13. Unmet Needs
14. Market Drivers and Barriers
15. Future Perspectives

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.